Fox Run Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-38,697	Closed	-$294K	–	917
2025 Q3	$294K	Buy	38,697 +20,972	+118%	+$175K	0.05%	692
2025 Q2	$159K	Sell	17,725 -11,700	-40%	-$109K	0.03%	773
2025 Q1	$221K	Sell	29,425 -38,615	-57%	-$311K	0.03%	770
2024 Q4	$512K	Buy	68,040 +27,406	+67%	+$208K	0.09%	434
2024 Q3	$309K	Buy	40,634 +4,522	+13%	+$34.4K	0.07%	528
2024 Q2	$223K	Buy	36,112 +17,594	+95%	+$97.1K	0.04%	636
2024 Q1	$94.1K	Sell	18,518 -523	-3%	-$2.94K	0.02%	708
2023 Q4	$114K	Sell	19,041 -6,435	-25%	-$37.3K	0.03%	675
2023 Q3	$180K	Buy	+25,476	New	+$183K	0.05%	580
2022 Q4	–	Sell	-19,854	Closed	-$250K	–	625
2022 Q3	$250K	Buy	19,854 +4,989	+34%	+$64.2K	0.1%	410
2022 Q2	$157K	Buy	+14,865	New	+$153K	0.08%	438
2017 Q4	–	Sell	-23,400	Closed	-$123K	–	671
2017 Q3	$123K	Buy	23,400 +700	+3%	+$3.58K	0.03%	639
2017 Q2	$126K	Buy	+22,700	New	+$138K	0.04%	587